Ergomed PLC operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Ergomed PLC with three other
companies in this sector in the United Kingdom:
Circassia Pharmaceuticals PLC
sales of £48.30 million [US$62.73 million]
of which 57%
GW Pharmaceuticals PLC
(£20.00 million [US$25.98 million]
of which 100%
was Novel Therapeutics), and
Oxford BioMedica plc
(£66.78 million [US$86.72 million]
of which 82%
During the year ended December of 2018, sales at
Ergomed PLC were £54.11 million (US$70.28 million).
increase of 13.6%
versus 2017, when the company's sales were £47.62 million.
This was the fifth consecutive year of sales increases at Ergomed PLC
(and since 2013, sales have increased a total of 257%).
Sales of Drug Safety and Medical Information Serv saw an increase
22.4% in 2018, from
£22.49 million to £27.53 million.